Danaher Corporation (NYSE:DHR) has earned a consensus rating of “Buy” from the nineteen analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $93.55.
A number of equities analysts recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Danaher Corporation from $87.00 to $97.00 and gave the stock an “outperform” rating in a research note on Friday. Morgan Stanley lifted their target price on shares of Danaher Corporation from $95.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday. Credit Suisse Group lifted their target price on shares of Danaher Corporation from $93.00 to $96.00 and gave the stock an “outperform” rating in a research note on Friday. Zacks Investment Research raised shares of Danaher Corporation from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a research note on Thursday, October 5th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $95.00 target price on shares of Danaher Corporation in a research note on Friday, September 8th.
Shares of Danaher Corporation (NYSE DHR) traded up 0.77% during trading on Friday, hitting $90.79. 4,113,494 shares of the stock traded hands. Danaher Corporation has a 1-year low of $76.27 and a 1-year high of $91.64. The firm has a market capitalization of $63.07 billion, a price-to-earnings ratio of 28.98 and a beta of 1.03. The firm has a 50-day moving average of $86.59 and a 200-day moving average of $84.29.
Danaher Corporation (NYSE:DHR) last announced its earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.48%. The business had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter last year, the firm earned $0.87 earnings per share. Danaher Corporation’s quarterly revenue was up 9.6% on a year-over-year basis. On average, equities analysts forecast that Danaher Corporation will post $3.97 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be issued a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date is Thursday, September 28th. Danaher Corporation’s dividend payout ratio is currently 16.52%.
WARNING: “Danaher Corporation (DHR) Receives Consensus Rating of “Buy” from Brokerages” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/22/danaher-corporation-dhr-receives-consensus-rating-of-buy-from-brokerages.html.
In other news, insider William King sold 43,688 shares of Danaher Corporation stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $82.86, for a total transaction of $3,619,987.68. Following the completion of the transaction, the insider now directly owns 45,748 shares in the company, valued at $3,790,679.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of Danaher Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $81.78, for a total transaction of $799,154.16. Following the transaction, the insider now owns 155,520 shares of the company’s stock, valued at $12,718,425.60. The disclosure for this sale can be found here. 12.20% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of DHR. BlackRock Inc. grew its holdings in shares of Danaher Corporation by 2,530.9% during the first quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock valued at $3,247,398,000 after buying an additional 36,524,795 shares during the last quarter. Flossbach Von Storch AG boosted its holdings in Danaher Corporation by 44.7% during the second quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock worth $487,945,000 after purchasing an additional 1,785,810 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Danaher Corporation by 3.9% during the first quarter. Vanguard Group Inc. now owns 40,967,631 shares of the conglomerate’s stock worth $3,503,962,000 after purchasing an additional 1,530,015 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Danaher Corporation by 16,410.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after purchasing an additional 1,476,901 shares during the last quarter. Finally, Koch Industries Inc. boosted its holdings in Danaher Corporation by 29,127.3% during the second quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after purchasing an additional 1,399,859 shares during the last quarter. Hedge funds and other institutional investors own 75.66% of the company’s stock.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.